ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of a Medical Device License (MDL) from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint. Covering both ClearPoint MRI-guidance and new iCT-guidance workflows in Canada, the MDL builds on the previously announced therapy delivery product clearance for the SmartFlow Neuro Cannula received in October 2025. This milestone reinforces ClearPoint's role as a global leader in integrated navigation and therapy delivery solutions and will enable the Company's biopharma partners to operate Canadian clinical trial and commercial sites using the same platform and standardized workflow already in use in the United States.